(thirdQuint)The BCD-089 (aIL6R) in Patients With Active Rheumatoid Arthritis.

 IL-6 is a new potential therapeutic target which plays important role in pathogenesis of several autoimmune disorders including rheumatoid arthritis.

 BCD-089 is a novel fully human monoclonal antibody against the interleukin-6 receptor developed by JCS BIOCAD (Russia) which is successfully passed phase I clinical study.

 Fixed dose of 162 mg was chosen for evaluation in phase II clinical trial.

 Comparisons in terms of efficacy, safety, PK/PD will be made for every week and every other week dosing for 54 weeks.

 W0-W12, planed as blinded, "main" period of the study, consists of three arms (n=35, each) - 2 study arms and placebo arm and served to test the hypothesis of superiority of BCD-089 to placebo.

 W12-W54, planned as "open" period of the study and served to evaluate long-therm safety and efficacy of BCD-089 in patients with active rheumatoid arthritis.

.

 The BCD-089 (aIL6R) in Patients With Active Rheumatoid Arthritis@highlight

The study is Phase II randomized, double-blind, placebo-controlled clinical trial to evaluate efficacy and safety, pharmacokinetics and pharmacodynamics of 2 dosing regimens (qw and q2w, s/c) of monoclonal antibody to IL6R (BCD-089) in patients with active rheumatoid arthritis and inadequate response to methotrexate.

